12/1
04:23 am
vktx
Assessing Viking Therapeutics (VKTX) Valuation After Recent Share Price Recovery [Yahoo! Finance]
Medium
Report
Assessing Viking Therapeutics (VKTX) Valuation After Recent Share Price Recovery [Yahoo! Finance]
11/29
01:13 pm
vktx
Viking Therapeutics (VKTX) VANQUISH-1 Trial Completes Early, H.C. Wainwright Retains Buy Rating [Yahoo! Finance]
Medium
Report
Viking Therapeutics (VKTX) VANQUISH-1 Trial Completes Early, H.C. Wainwright Retains Buy Rating [Yahoo! Finance]
11/25
04:05 pm
vktx
Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference
Low
Report
Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference
11/25
05:21 am
vktx
Viking Therapeutics (VKTX) Balances Rising R&D Costs With Clinical Progress: Is the Risk Worth the Potential? [Yahoo! Finance]
Medium
Report
Viking Therapeutics (VKTX) Balances Rising R&D Costs With Clinical Progress: Is the Risk Worth the Potential? [Yahoo! Finance]
11/21
05:31 am
vktx
Viking Therapeutics (NASDAQ:VKTX) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Low
Report
Viking Therapeutics (NASDAQ:VKTX) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
11/21
04:31 am
vktx
Viking Therapeutics, Up 62% Since August, Undercuts A Buy Zone Despite Key Win [Yahoo! Finance]
Low
Report
Viking Therapeutics, Up 62% Since August, Undercuts A Buy Zone Despite Key Win [Yahoo! Finance]
11/19
03:03 am
vktx
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735 [Yahoo! Finance]
Medium
Report
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735 [Yahoo! Finance]
11/19
02:55 am
vktx
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735
Medium
Report
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735
11/17
03:41 am
vktx
Viking Therapeutics (VKTX): Assessing Valuation Following Recent 16.6% Share Price Rebound [Yahoo! Finance]
Medium
Report
Viking Therapeutics (VKTX): Assessing Valuation Following Recent 16.6% Share Price Rebound [Yahoo! Finance]
11/12
08:18 am
vktx
Viking Therapeutics (NASDAQ:VKTX) had its price target raised by analysts at Canaccord Genuity Group Inc. from $106.00 to $107.00. They now have a "buy" rating on the stock.
Medium
Report
Viking Therapeutics (NASDAQ:VKTX) had its price target raised by analysts at Canaccord Genuity Group Inc. from $106.00 to $107.00. They now have a "buy" rating on the stock.
11/8
12:52 pm
vktx
Will New Cardiometabolic Data on VK2735 Shift Viking Therapeutics' (VKTX) Obesity Treatment Narrative? [Yahoo! Finance]
Low
Report
Will New Cardiometabolic Data on VK2735 Shift Viking Therapeutics' (VKTX) Obesity Treatment Narrative? [Yahoo! Finance]
11/6
08:06 am
vktx
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025 [Yahoo! Finance]
Low
Report
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025 [Yahoo! Finance]
11/6
07:05 am
vktx
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025
Low
Report
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025
11/4
07:41 pm
vktx
Lightning Round: I lack a catalyst to recommend Zoom, says Jim Cramer [CNBC]
Medium
Report
Lightning Round: I lack a catalyst to recommend Zoom, says Jim Cramer [CNBC]
11/4
04:05 pm
vktx
Viking Therapeutics to Participate at Upcoming Investor Conferences
Medium
Report
Viking Therapeutics to Participate at Upcoming Investor Conferences
10/30
03:59 pm
vktx
Viking Therapeutics (NASDAQ:VKTX) was upgraded by analysts at Canaccord Genuity Group Inc. to a "strong-buy" rating.
Low
Report
Viking Therapeutics (NASDAQ:VKTX) was upgraded by analysts at Canaccord Genuity Group Inc. to a "strong-buy" rating.
10/29
04:05 pm
vktx
Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025
Medium
Report
Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025
10/29
06:01 am
vktx
Viking Therapeutics (NASDAQ:VKTX) was given a new $106.00 price target on by analysts at Canaccord Genuity Group Inc..
Low
Report
Viking Therapeutics (NASDAQ:VKTX) was given a new $106.00 price target on by analysts at Canaccord Genuity Group Inc..
10/25
07:13 am
vktx
Viking Therapeutics (NASDAQ:VKTX) was upgraded by analysts at B. Riley to a "strong-buy" rating.
Medium
Report
Viking Therapeutics (NASDAQ:VKTX) was upgraded by analysts at B. Riley to a "strong-buy" rating.
10/24
08:10 pm
vktx
New VK2735 Dosing Trial Might Change the Case for Investing in Viking Therapeutics (VKTX) [Yahoo! Finance]
Medium
Report
New VK2735 Dosing Trial Might Change the Case for Investing in Viking Therapeutics (VKTX) [Yahoo! Finance]
10/24
09:27 am
vktx
Viking Therapeutics (NASDAQ:VKTX) had its price target lowered by analysts at JPMorgan Chase & Co. from $80.00 to $75.00. They now have an "overweight" rating on the stock.
Low
Report
Viking Therapeutics (NASDAQ:VKTX) had its price target lowered by analysts at JPMorgan Chase & Co. from $80.00 to $75.00. They now have an "overweight" rating on the stock.
10/23
09:08 am
vktx
Viking Therapeutics (NASDAQ:VKTX) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
Viking Therapeutics (NASDAQ:VKTX) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
10/23
08:42 am
vktx
Viking Therapeutics (NASDAQ:VKTX) was given a new $105.00 price target on by analysts at Cantor Fitzgerald.
Low
Report
Viking Therapeutics (NASDAQ:VKTX) was given a new $105.00 price target on by analysts at Cantor Fitzgerald.
10/23
06:16 am
vktx
Viking Therapeutics (NASDAQ:VKTX) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Medium
Report
Viking Therapeutics (NASDAQ:VKTX) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
10/22
04:05 pm
vktx
Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Medium
Report
Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update